Cotadutide
Also known as: MEDI0382
Balanced dual GLP-1/glucagon receptor agonist; weight loss + hepatic glucose output reduction + increased energy expenditure.
- Typical dose
- 100 mcg – 300 mcg
- Frequency
- once daily
- Route
- Subcutaneous
- Half-life
- 14 hours
- Routes
- Subcutaneous
- Status
- Program discontinued by AstraZeneca (2023)
Benefits
- Weight loss
- Blood sugar control
- Liver fat reduction
- Dual-hormone action
Dosing
A common research range for Cotadutide is 100 mcg to 300 mcg once daily. Daily injection; titrate slowly. These figures are reference points from published literature, not a prescription — your protocol should be set with a licensed provider.
Half-life
Cotadutide has an approximate half-life of 14 hours. Vial can display informational half-life estimates when supported data is available. These estimates are not measured blood concentrations or dosing instructions.
Storage
2-8°C.
Reported side effects
- Nausea
- Diarrhea
- Decreased appetite
- Vomiting
Contraindications
- MEN2
- Pancreatitis
- Severe renal impairment
Track Cotadutide with Vial
Vial logs every Cotadutide dose, organizes your schedule, and offers reconstitution math and supported half-life estimates. Tracking records stay on your device. A Vial Pro subscription is required. Download Vial on the App Store →
This page is for educational and harm-reduction purposes only. Cotadutide is not FDA-approved for most uses described here. Always consult a licensed physician before starting any peptide protocol. Vial does not sell peptides, recommend vendors, or provide medical advice.